Výsledky vyhledávání

Economic impact of industry-sponsored clinical trials of pharmaceutical products in Austria

Autor: Christian Baumgartner, Dejan Baltic, Johannes Pleiner-Duxneuner, Christina Ornauer, Alexander Celedin, Marco Voit, Stefan Thomas Kaehler, Gerald Eichhober, Wolfgang Bonitz, Helga Tieben, Christa Holzhauser, Georg Pum, Botond Ponner, Isabella Presch, Gertrude Weingartmann, Evelyn Walter, Bernhard Mraz

Publikováno v: Journal of Medical Economics. 23:566-574

Aims: Modern pharmaceutical product development is a long and complex process associated with significant investments by pharmaceutical companies. The innovative pharmaceutical industry accounts for the vast majority of expenditures in clinical trial

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::a240ed6e5973c83c1d3c07fb2488c59d
https://doi.org/10.1080/13696998.2020.1728977

Zobrazit plný text záznamu

251 Rapid and sustained improvements in patient-reported outcomes with ixekizumab in biologic-naïve and TNF-inadequate responder patients with psoriatic arthritis

Autor: Katrien Van Beneden, Andrew J Bradley, Hasan Tahir, Georg Pum, Mani H Nassab

Publikováno v: Rheumatology. 58

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::c41a4493ba2fdd29e5ea490d223d3e53
https://doi.org/10.1093/rheumatology/kez107.067

Zobrazit plný text záznamu

248 Sustained improvements in disease activity for up to two-years with ixekizumab in patients with active psoriatic arthritis who were either biologic-naïve or with previous inadequate response to tumour necrosis factor inhibitor therapy

Autor: Andrew J Bradley, Katrien Van Beneden, Mani H Nassab, Deepak R. Jadon, Georg Pum

Publikováno v: Rheumatology. 58

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::de2a7a7a4245403bf2a5ba508d83d958
https://doi.org/10.1093/rheumatology/kez107.064

Zobrazit plný text záznamu

216. BARICITINIB, METHOTREXATE, OR BARICITINIB PLUS METHOTREXATE IN PATIENTS WITH MODERATELY-TO-SEVERELY ACTIVE RHEUMATOID ARTHRITIS WHO HAD RECEIVED LIMITED OR NO TREATMENT WITH DMARDS: EFFICACY AND SAFETY RESULTS FROM THE 52-WEEK PHASE 3 RA-BEGIN STUDY

Publikováno v: Rheumatology. 56

Background: Baricitinib, an oral JAK1/JAK2 inhibitor, improves disease activity with an acceptable safety profile in patients with active rheumatoid arthritis (RA). We report efficacy and safety data for baricitinib as monotherapy or in combination w

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::ba597cc5b6e0940b7d894eabcf3cd622
https://doi.org/10.1093/rheumatology/kex062.217

Zobrazit plný text záznamu

Effect of clindamycin hydrochloride on gingival crevicular fluid and immune mediators in beagles

Autor: Karl, Zetner, Georg, Pum, Wolf-Dieter, Rausch, Xio-Hui, Rausch-Fan, Shui Ting, Hung

Publikováno v: Veterinary therapeutics : research in applied veterinary medicine. 3(2)

Gingivitis and periodontitis, two frequently observed conditions in dogs, are primarily caused by bacterial plaque. Gingival crevicular fluid (GCF) and some of the biochemical substances contained in it are used diagnostically and to evaluate the suc

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=pmid________::5fdf02a2ac12f73ef73ecb967706ea6b
https://pubmed.ncbi.nlm.nih.gov/19750749

Zobrazit plný text záznamu

Vyhledávací nástroje:

Upřesnit hledání